Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 10 Key Players companies in Ribociclib
by Most News Heat in the United Kingdom in 2019

The Ribociclib top 10 is Discovery PatSnap’ annual ranking of the top 10 Most News Heat Ribociclib Key Players in the United Kingdom. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2019, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
Medicine,Health care,Side effect,
...[+2]
news: 13
2
Health care,Clinical trial,Drug,
...[+2]
news: 6
3
Safety monitoring,Contract research organization,Laboratory testing,
...[+2]
news: 5
4
news: 2
5
Oncology drugs,Abemaciclib,Cyclin-dependent kinase 9,
...[+2]
news: 2
6
Investment banking,Retail banking,Underwriting,
...[+2]
news: 1
7
Funeral home,Food industry,Prebiotic,
...[+2]
news: 1
8
NHS England
Health care,Public participation,Rigour,
...[+2]
news: 1
9
The Christie NHS Foundation Trust
news: 1
10
G1 Ventures
news: 1
Page generation time: Jul 08 2025